Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
Kuehn Law Encourages ALPN, JBT, ELYM, and HRT Investors to Contact Law Firm
PR Newswire
NEW YORK, April 11, 2024
NEW YORK, April 11, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:
- Alpine Immune Sciences, Inc. (NASDAQ: ALPN) click to participate
Alpine Immune Sciences, Inc. has agreed to be acquired by Vertex Pharmaceuticals Incorporated. Under the proposed transaction, Alpine shareholders will receive $65.00 per share.
- JBT Corporation (NYSE: JBT) click to participate
JBT Corporation entered into a merger agreement with Marel hf. Shareholders of Marel will have the option to receive either €3.60 per share in cash, all in JBT common stock for 0.0407 per share, or a combination of cash and JBT for €1.26 in cash and 0.0265 JBT shares.
- Eliem Therapeutics, Inc. (NASDAQ: ELYM) click to participate
Eliem Therapeutics, Inc. has entered into an agreement to acquire Tenet Medicines Inc., under which Tenet's shareholders will be compensated with new shares representing 15.4% of Eliem's common stock following the transaction's closure.
- HireRight Holdings Corporation (NYSE: HRT) click to participate
HireRight Holdings Corporation has agreed to merge with affiliates of General Atlantic, L.P. and Stope Point Capital LLC for $14.35 per share in cash.
Why Your Participation Matters:
As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™
How to Get Involved:
Kuehn Law is dedicated to safeguarding shareholder interests. Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at justin@kuehn.law or call (833) 672-0814. Kuehn Law covers all case costs and does not charge its investor clients. Shareholders are advised to act promptly, as legal rights may be time-sensitive. For additional information, please visit Merger Litigation - Kuehn Law.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
justin@kuehn.law
(833) 672-0814
SOURCE Kuehn Law, PLLC
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast